Reference list:
1. Perinatal and Maternal Mortality Review Committee. Fifteenth Annual
Report of the Perinatal and Maternal Mortality Review Committee
| Te Pūrongo ā-Tau Tekau mā Rima o te Komiti Arotake Mate Pēpi,
Mate Whaea Hoki: Reporting Mortality and Morbidity 2020 | Te
Tuku Pūrongo mō te Mate me te Whakamate 2020. Wellington: Health Quality
& Safety Commission; 2022.
2. Mozooni M, Preen DB, Pennell CE. Stillbirth in Western Australia,
2005–2013: The influence of maternal migration and ethnic origin. Med J
Aust. 2018; 209(9):394-400.
3. Davies-Tuck ML, Davey M-A, Wallace EM. Maternal region of birth and
stillbirth in Victoria, Australia 2000–2011: A retrospective cohort
study of Victorian perinatal data. PLoS One. 2017; 12(6):e0178727.
4. Li Y, Quigley MA, Macfarlane A, Jayaweera H, Kurinczuk JJ, Hollowell
J. Ethnic differences in singleton preterm birth in England and Wales,
2006-12: Analysis of national routinely collected data. Paediatr Perinat
Epidemiol. 2019; 33(6):449-58.
5. Ministry of Health. Report on Maternity web tool: Wellington:
Ministry of Health; 2020 [Available from:
https://www.health.govt.nz/publication/report-maternity-web-tool].
6. Draper ES, Gallimore ID, Smith LK, Fenton AC, Kurinczuk JJ, Smith PW,
et al, on behalf of the MBRRACE-UK Collaboration. MBRRACE-UK perinatal
mortality surveillance report, UK perinatal deaths for births from
January to December 2018. Leicester: The Infant Mortality and Morbidity
Studies, Department of Health Sciences, University of Leicester; 2020.
7. Bartsch E, Park AL, Pulver AJ, Urquia ML, Ray JG. Maternal and
paternal birthplace and risk of stillbirth. J Obstet Gynaecol Can. 2015;
37(4):314-23.
8. De Graaff E, Sadler L, Lakhdhir H, Simon-Kumar R, Peiris-John R,
Burgess W, et al. An in-depth analysis of perinatal related mortality
among women of South Asian ethnicity in Aotearoa New Zealand. BMC
Pregnancy Childbirth. 2023; 23(1):535.
9. Hedderson MM, Darbinian JA, Ferrara A. Disparities in the risk of
gestational diabetes by race-ethnicity and country of birth. Paediatr
Perinat Epidemiol. 2010; 24(5):441-8.
10. Mukerji G, Chiu M, Shah BR. Gestational diabetes mellitus and
pregnancy outcomes among Chinese and South Asian women in Canada. J
Matern Fetal Neonatal Med. 2013; 26(3):279-84.
11. Audette MC, Levytska K, Lye SJ, Melamed N, Kingdom JC. Parental
ethnicity and placental maternal vascular malperfusion pathology in
healthy nulliparous women. Placenta. 2018; 66:40-6.
12. Urquia M, Glazier RH, Berger H, Ying I, De Souza L, Ray JG.
Gestational diabetes among immigrant women. Epidemiol. 2011;
22(6):879-80.
13. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. Deriving
ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes
Care. 2011; 34(8):1741-8.
14. Hedderson M, Ehrlich S, Sridhar S, Darbinian J, Moore S, Ferrara A.
Racial/ethnic disparities in the prevalence of gestational diabetes
mellitus by BMI. Diabetes Care. 2012; 35(7):1492-8.
15. Bryant M, Santorelli G, Lawlor DA, Farrar D, Tuffnell D, Bhopal R,
et al. A comparison of South Asian specific and established BMI
thresholds for determining obesity prevalence in pregnancy and
predicting pregnancy complications: findings from the Born in Bradford
cohort. Int J Obes. 2014; 38(3):444-50.
16. De Graaff E, Sadler L, Lakhdhir H, Simon-Kumar R, Peiris-John R,
Burgess W, et al. Grouping women of South Asian ethnicity for pregnancy
research in New Zealand. Aust N Z J Obstet Gynaecol. 2022;
63(4):499-508.
17. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2
diabetes in South Asians: Similarities and differences with white
Caucasian and other populations. Ann N Y Acad Sci. 2013; 1281(1):51-63.
18. Parackal S, Coppell K, Yang CL, Sullivan T, Subramaniam RM. Hidden
figures and misnomers: a case for disaggregated Asian health statistics
in Aotearoa New Zealand to improve health outcomes. N Z Med J. 2021;
134(1546):109-16.
19. Volgman AS, Palaniappan LS, Aggarwal NT, Gupta M, Khandelwal A,
Krishnan AV, et al. Atherosclerotic cardiovascular disease in South
Asians in the United States: Epidemiology, risk factors, and treatments:
A scientific statement from the American Heart Association. Circ. 2018;
138(1):e1-e34.
20. Wali M, Ram CVS. Metabolic Syndrome in South Asians. In: Ahima RS,
editor. Metabolic Syndrome: A Comprehensive Textbook. Cham: Springer
International Publishing; 2016. p. 73-85.
21. Williamson K, Gunn AJ, Johnson N, Milsom SR. The impact of ethnicity
on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet
Gynaecol. 2001; 41(2):202-6.
22. Sletner L, Jenum AK, Qvigstad E, Hammerstad SS. Thyroid function
during pregnancy in a multiethnic population in Norway. J Endocr Soc.
2021; 5(7): bvab078.
23. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S, et
al. Detection of thyroid dysfunction in early pregnancy: Universal
screening or targeted high-risk case finding? J Clin Endocrinol Metab.
2007; 92(1):203-7.
24. Fischbacher C, Bhopal R, Patel S, White M, Unwin N, Alberti KG.
Anaemia in Chinese, South Asian, and European populations in Newcastle
upon Tyne: Cross sectional study. BMJ (Clinical research ed). 2001;
322(7292):958-9.
25. Sattar N, Greer IA. Pregnancy complications and maternal
cardiovascular risk: Opportunities for intervention and screening? BMJ
(Clinical research ed). 2002; 325(7356):157-60.
26. International Diabetes Federation. The IDF worldwide defi nition of
the metabolic syndrome. 2006.
27. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, Leemaqz SY, Poston L,
McCowan LM, et al. Metabolic syndrome in pregnancy and risk for adverse
pregnancy outcomes: A prospective cohort of nulliparous women. PLoS Med.
2018; 15(12):e1002710.
28. de Graaff E, Bartlett K, Sadler L, Lakhdhir H, Simon-Kumar R,
Peiris-John R, et al. Placental pathology findings amongst extremely
preterm perinatal deaths in Aotearoa New Zealand. Placenta. 2023;
137:78-87.
29. Cox P, Cohen MC, Scheimberg IB. Acute Chorioamnionitis. In: Khong
TY, Mooney EE, Nikkels PGJ, Morgan TK, Gordijn SJ, editors. Pathology of
the Placenta: A Practical Guide. Cham: Springer International
Publishing; 2019. p. 103-7.
30. Pantham P, Aye ILMH, Powell TL. Inflammation in maternal obesity and
gestational diabetes mellitus. Placenta. 2015; 36(7):709-15.
31. Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V,
et al. Inflammation in complicated pregnancy and its outcome. Am J
Perinatol. 2016; 33(14):1337-56.
32. Zhang X, Liao Q, Wang F, Li D. Association of gestational diabetes
mellitus and abnormal vaginal flora with adverse pregnancy outcomes.
Medicine. 2018; 97(34):e11891.
33. Scholl TO, Sowers M, Chen X, Lenders C. Maternal glucose
concentration influences fetal growth, gestation, and pregnancy
complications. Am J Epidemiol. 2001; 154(6):514-20.
34. McCoy J, Downes KL, Levine LD. 840: Risk factors associated with
development of chorioamnionitis during labor induction with a
standardized labor protocol. Am J Obstet Gynecol. 2018; 218(1):S501-S2.
35. McCowan L, North R, Taylor R. ACTRN12607000551493. Australian New
Zealand Clinical Trials Registry. www.anzctr.org.au/trialSearch.aspx;
2007.
36. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al.
Early pregnancy prediction of preeclampsia in nulliparous women,
combining clinical risk and biomarkers: The Screening for Pregnancy
Endpoints (SCOPE) international cohort study. Hypertens. 2014;
64(3):644-52.
37. WHO. Physical status: the use and interpretation of anthropometry.
Report of a WHO Expert Committee. 1995.
38. WHO expert consultation. Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies.
Lancet. 2004; 363(9403):157-63.
39. World Health Organization Regional Office for the Western Pacific.
The Asia-Pacific perspective: Redefining obesity and its treatment.
2000.
40. Galbraith C, Jenkin G, Davis P, Coope P. New Zealand Social Economic
Index 1996 Users Guide. Statistics New Zealand, Wellington; 2003.
41. Gardosi J, Francis A. Customised Weight Centile Calculator. GROW
v6.7.8. Gestation Network, www.gestation.net, 2016.
42. Lim K, Beck KL, Von Hurst PR, Rutherfurd-Markwick KJ, Badenhorst CE.
Iron deficiency and risk factors in pre-menopausal females living in
Auckland, New Zealand. Asia Pac J Clin Nutr. 2020; 29(3):638-47.
43. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and
cardiovascular disease: Metabolic syndrome of pregnancy? Atheroscler.
2004; 175(2):189-202.
44. Bartels Ä, Egan N, Broadhurst DI, Khashan AS, Joyce C, Stapleton M,
et al. Maternal serum cholesterol levels are elevated from the 1st
trimester of pregnancy: A cross-sectional study. J Obstet Gynaecol.
2012; 32(8):747-52.
45. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;
26(4):364-73.
46. Ryckman K, Spracklen C, Smith C, Robinson J, Saftlas A. Maternal
lipid levels during pregnancy and gestational diabetes: a systematic
review and meta-analysis. BJOG. 2015; 122(5):643-51.
47. Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of
adiponectin in inflammation and diseases. Int J Mol Sci. 2020;
21(4):1219.
48. Vecchiola A, García K, González-Gómez LM, Tapia-Castillo A, Artigas
R, Baudrand R, et al. Plasminogen activator inhibitor-1 and adiponectin
are associated with metabolic syndrome components. Am J Hypertens. 2021;
35(4):311-8.
49. Moore S, Daniel M, Auger N. Socioeconomic disparities in low birth
weight outcomes according to maternal birthplace in Québec, Canada. Ethn
Health. 2009; 14(1):61-74..
50. Kelly Y, Panico L, Bartley M, Marmot M, Nazroo J, Sacker A. Why does
birthweight vary among ethnic groups in the UK? Findings from the
Millennium Cohort Study. J Public Health. 2008; 31(1):131-7.
51. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman
DG, et al. International standards for newborn weight, length, and head
circumference by gestational age and sex: The Newborn Cross-Sectional
Study of the INTERGROWTH-21st Project. Lancet. 2014; 384(9946):857-68.
52. Williams LA, Evans SF, Newnham JP. Prospective cohort study of
factors influencing the relative weights of the placenta and the newborn
infant. BMJ. 1997; 314(7098):1864-8.
53. Ng QJ, Han JY, Saffari SE, Yeo GS-H, Chern BSM, Tan KH. Longitudinal
circulating placental growth factor (PlGF) and soluble FMS-like tyrosine
kinase-1 (sFlt-1) concentrations during pregnancy in Asian women: a
prospective cohort study. BMJ Open. 2019; 9(5):e028321.
54. De Falco S. The discovery of placenta growth factor and its
biological activity. Exp Mol Med 2012; 44(1):1-9.
55. Kang M, Jeong J, Lee J, Park S, Sung Y, Choi M, et al. Placental
growth factor (PlGF) is linked to inflammation and metabolic disorders
in mice with diet-induced obesity. Endocr J. 2018; 65(4):437-47.
56. Pervanidou P, Chouliaras G, Akalestos A, Bastaki D, Apostolakou F,
Papassotiriou I, et al. Increased placental growth factor (PlGF)
concentrations in children and adolescents with obesity and the
metabolic syndrome. Hormones. 2014; 13(3):369-74.
57. Siervo M, Ruggiero D, Sorice R, Nutile T, Aversano M, Stephan BCM,
et al. Angiogenesis and biomarkers of cardiovascular risk in adults with
metabolic syndrome. J Intern Med. 2010; 268(4):338-47.
58. Duran EK, Cook NR, Bobadilla M, Kim E, Manson JE, Buring JE, et al.
Plasma placental growth factor concentrations are elevated well in
advance of type 2 diabetes mellitus onset: Prospective data from the
WHS. J Am Heart Assoc. 2019; 8(15):e012790.
59. Eleftheriades M, Papastefanou I, Lambrinoudaki I, Kappou D, Lavranos
D, Akalestos A, et al. Elevated placental growth factor concentrations
at 11–14weeks of gestation to predict gestational diabetes mellitus.
Metabol. 2014; 63(11):1419-25.
60. Nuzzo AM, Giuffrida D, Moretti L, Re P, Grassi G, Menato G, et al.
Placental and maternal sFlt1/PlGF expression in gestational diabetes
mellitus. Sci Rep. 2021; 11(1):2312.
61. Gorkem U, Togrul C, Arslan E. Relationship between elevated serum
level of placental growth factor and status of gestational diabetes
mellitus. J Matern Fetal Neonatal Med. 2020; 33(24):4159-63.
62. Yanachkova V, Staynova R, Stankova T, Kamenov Z. Placental growth
factor and pregnancy-associated plasma protein-A as potential early
predictors of gestational diabetes mellitus. Medicina. 2023; 59(2):398.
63. Venkata Surekha M, Singh S, Sarada K, Sailaja G, Balakrishna N,
Srinivas M, et al. Study on the effect of severity of maternal iron
deficiency anemia on regulators of angiogenesis in placenta. Fetal
Pediatr Pathol. 2019; 38(5):361-75.
64. Cvitic S, Desoye G, Hiden U. Glucose, insulin, and oxygen interplay
in placental hypervascularisation in diabetes mellitus. Biomed Res Int.
2014; 2014:145846.
65. Burton GJ, Cindrova-Davies T, Yung Hw, Jauniaux E. Hypoxia and
reproductive health: Oxygen and development of the human placenta.
Reprod. 2021; 161(1):F53-F65.
66. Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone
S. Adipokines: New potential therapeutic target for obesity and
metabolic, rheumatic, and cardiovascular diseases. Front Physiol. 2020;
11: 578966.
67. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al.
Lipocalin-2 is an inflammatory marker closely associated with obesity,
insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;
53(1):34-41.
68. Guo H, Jin D, Zhang Y, Wright W, Bazuine M, Brockman DA, et al.
Lipocalin-2 deficiency impairs thermogenesis and potentiates
diet-induced insulin resistance in mice. Diabetes. 2010; 59(6):1376-85.
69. Meyers K, López M, Ho J, Wills S, Rayalam S, Taval S. Lipocalin-2
deficiency may predispose to the progression of spontaneous age-related
adiposity in mice. Sci Rep. 2020; 10(1):14589.
70. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, et al.
The role of periostin in tissue remodeling across health and disease.
Cell Mol Life Sci. 2014; 71(7):1279-88.
71. Landry NM, Cohen S, Dixon IMC. Periostin in cardiovascular disease
and development: A tale of two distinct roles. Basic Res Cardiol. 2017;
113(1):1.
72. Azharuddin M, Kapur P, Sharma M. Circulating periostin level as a
potential biomarker for early cardiovascular risk in subjects with
type-2 diabetes mellitus: Evidence from a cross-sectional study. Metab.
2021; 116:154499.
73. Luo Y, Qu H, Wang H, Wei H, Wu J, Duan Y, et al. Plasma periostin
levels are increased in Chinese subjects with obesity and type 2
diabetes and are positively correlated with glucose and lipid
parameters. Mediators Inflamm. 2016; 2016:6423637.
74. Chen X, Huo L, Ren L, Li Y, Sun Y, Li Y, et al. Polycystic ovary
syndrome is associated with elevated periostin levels. Exp Clin
Endocrinol Diabetes. 2019; 127(09):571-7.
75. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, et
al. Diabetes mellitus enhances vascular matrix metalloproteinase
activity: Role of oxidative stress. Circ Res. 2001; 88(12):1291-8.
76. Gonçalves FM, Jacob-Ferreira ALB, Gomes VA, Casella-Filho A, Chagas
ACP, Marcaccini AM, et al. Increased circulating levels of matrix
metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in
patients with metabolic syndrome. Clin Chim Acta. 2009; 403(1):173-7.
77. Anderson JG, Baer RJ, Partridge JC, Kuppermann M, Franck LS, Rand L,
et al. Survival and major morbidity of extremely preterm infants: A
population-based study. Pediatr. 2016; 138(1):e20154434.
78. Chen X, Scholl TO. Maternal biomarkers of endothelial dysfunction
and preterm delivery. PLoS One. 2014; 9(1):e85716.
79. Raba G, Tabarkiewicz J. Cytokines in preterm delivery: Proposal of a
new diagnostic algorithm. J Immunol Res. 2018; 2018:8073476.
80. Davutoglu EA, Fırat AA, Ozel A, Madazli R. Assessment of the
circulating soluble endothelial cell adhesion molecules and pentraxin 3
levels in predicting preterm delivery within 72 hours. Int J Med
Biochem. 2023; 6(1):1-7.
81. Marvin KW, Keelan JA, Zhou RLI, Mitchell MD, McCowan LME, Coleman
MAG. Intercellular adhesion molecule-1 (ICAM-1) in cervicovaginal fluid
of women presenting with preterm labor: Predictive value for preterm
delivery. Am J Reprod Immunol. 2000; 43(5):264-71.
82. Marvin KW, Keelan JA, Sato TA, Coleman MA, McCowan LM, Miller HC, et
al. Enhanced expression of intercellular adhesion molecule-1 (ICAM-1) in
amnion with term and preterm labour. Placenta. 2000; 21(1):115-21.
83. Bui TM, Wiesolek HL, Sumagin R. ICAM-1: A master regulator of
cellular responses in inflammation, injury resolution, and
tumorigenesis. J Leukoc Biol. 2020; 108(3):787-99.
84. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial
dysfunction in metabolic syndrome: Prevalence, pathogenesis and
management. Nutr Metab Cardiovasc Dis. 2010; 20(2):140-6.
85. Lee HA, Choi EJ, Park B, Lee H, Hong YS, Kim HS, et al. The
association between metabolic components and markers of inflammatory and
endothelial dysfunction in adolescents, based on the Ewha Birth and
Growth Cohort Study. PLoS One. 2020; 15(5):e0233469.
86. Sajadi S, Khoramdelazad H, Hassanshahi G, Rafatpanah H, Hosseini J,
Mahmoodi M, et al. Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10)
are elevated in type 2 diabetic patients: Evidence for the involvement
of inflammation and angiogenesis/angiostasis in this disease state. Clin
Lab. 2013; 59(1-2):133-7.
87. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A,
Theisl A, et al. Multiplex bead analysis of vitreous and serum
concentrations of inflammatory and proangiogenic factors in diabetic
patients. Mol Vis. 2008; 14:637-43.
88. Tisato V, Toffoli B, Monasta L, Bernardi S, Candido R, Zauli G, et
al. Patients affected by metabolic syndrome show decreased levels of
circulating platelet derived growth factor (PDGF)-BB. Clin Nutr. 2013;
32(2):259-64.
89. Kochumon S, Madhoun AA, Al-Rashed F, Azim R, Al-Ozairi E, Al-Mulla
F, et al. Adipose tissue gene expression of CXCL10 and CXCL11 modulates
inflammatory markers in obesity: Implications for metabolic inflammation
and insulin resistance. Ther Adv Endocrinol Metab. 2020;
11:2042018820930902.
90. Azar Sharabiani MT, Vermeulen R, Scoccianti C, Hosnijeh FS, Minelli
L, Sacerdote C, et al. Immunologic profile of excessive body weight.
Biomark. 2011; 16(3):243-51.
91. Weidmann P, Saxenhofer H, Shaw SG, Ferrier C. Atrial natriuretic
peptide in man. J Steroid Biochem. 1989; 32(1, Part 2):229-41.
92. Cannone V, Cabassi A, Volpi R, Burnett JC. Atrial natriuretic
peptide: A molecular target of novel therapeutic approaches to
cardio-metabolic disease. Int J Mol Sci. 2019; 20(13):3265.
93. Schlueter N, de Sterke A, Willmes DM, Spranger J, Jordan J,
Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic
potential in the metabolic syndrome. Pharmacol Ther. 2014; 144(1):12-27.
94. Marjara J, Scott C, Adel F, Chen HH. Predicting the development of
metabolic syndrome and diabetes in healthy patients using serum insulin,
atrial natriuretic peptide, and aldosterone levels. J Am Coll Cardiol.
2023; 81(8_Supplement):1813.
95. Magnusson M, Jujic A, Hedblad B, Engström G, Persson M, Struck J, et
al. Low plasma level of atrial natriuretic peptide predicts development
of diabetes: the prospective Malmo Diet and Cancer study. J Clin
Endocrinol Metab. 2012; 97(2):638-45.
96. Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, Tasci Y.
Prediction of gestational diabetes mellitus in the first trimester:
comparison of maternal fetuin-A, N-terminal proatrial natriuretic
peptide, high-sensitivity C-reactive protein, and fasting glucose
levels. Arch Endocrinol Metab. 2019; 63:121-7.
97. Yuksel MA, Davutoglu AE, Temel Yuksel I, Kucur M, Ekmekci H, Balci
Ekmekci O, et al. Maternal serum atrial natriuretic peptide (ANP) and
brain-type natriuretic peptide (BNP) levels in gestational diabetes
mellitus. J Matern Fetal Neonatal Med. 2016; 29(15):2527-30.
98. Bennett PC, Gill PS, Silverman S, Blann AD, Balakrishnan B, Lip GYH.
Ethnic/racial differences in circulating markers of angiogenesis and
their association with cardiovascular risk factors and cardiovascular
disease. Int J Cardiol. 2013; 167(4):1247-50.
99. Kolben M, Bläser J, Ulm K, Schmitt M, Schneider KTM, Tschesche H, et
al. Angiogenin plasma levels during pregnancy. Am J Obstet Gynecol.
1997; 176(1, Part 1):37-41.
100. Pavlov N, Frendo JL, Guibourdenche J, Degrelle SA, Evain-Brion D,
Badet J. Angiogenin expression during early human placental development;
association with blood vessel formation. Biomed Res Int. 2014;
2014:781632.
101. Yu D, Cai Y, Zhou W, Sheng J, Xu Z. The potential of angiogenin as
a serum biomarker for diseases: Systematic review and meta-analysis. Dis
Markers. 2018; 2018:1984718.
102. Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H,
et al. Soluble ST2 associates with diabetes but not established
cardiovascular risk factors: A new inflammatory pathway of relevance to
diabetes? PLoS One. 2012; 7(10):e47830.
103. Sabbatinelli J, Giuliani A, Bonfigli AR, Ramini D, Matacchione G,
Campolucci C, et al. Prognostic value of soluble ST2, high-sensitivity
cardiac troponin, and NT-proBNP in type 2 diabetes: A 15-year
retrospective study. Cardiovasc Diabetol. 2022; 21(1):180.
104. Zong X, Fan Q, Zhang H, Yang Q, Xie H, Chen Q, et al. Soluble ST2
levels for predicting the presence and severity of metabolic syndrome.
Endocr Connect. 2021; 10(3):336-44.